In short
Deferoxamine Mesilate, also known as Deferoxamine Mesylate or DFO, is being investigated in several clinical trials for its potential to improve outcomes in patients with various types of stroke, including intracerebral hemorrhage and subarachnoid hemorrhage. This iron-chelating agent is being studied for its ability to reduce brain damage and improve functional outcomes in stroke patients. The trials aim to determine the safety, tolerability, and efficacy of Deferoxamine Mesilate in different dosages and administration methods.
At a glance
- Drug Name
- Deferoxamine Mesilate (also known as Deferoxamine Mesylate or DFO)
- Mechanism
- Iron-chelating agent, potentially reducing brain damage by removing excess iron
- Stroke Types Studied
- Intracerebral Hemorrhage (ICH), Subarachnoid Hemorrhage (SAH)
- Administration
- Intravenous infusion, typically 32 mg/kg/day for 3-5 consecutive days
- Primary Outcomes
- Functional neurological status (modified Rankin Scale), safety, tolerability
- Secondary Outcomes
- Brain swelling, iron levels, quality of life, length of hospital stay
- Trial Designs
- Phase II, randomized, placebo-controlled, adaptive platform trials
- Potential Benefits
- Improved functional outcomes, reduced brain damage, decreased disability
- Monitored Side Effects
- Allergic reactions, blood pressure changes, visual/auditory changes
- Current Status
- Ongoing clinical trials to determine efficacy and optimal dosing
What is Deferoxamine Mesylate?
Deferoxamine Mesylate, also known as DFO, Desferal, or deferoxamine, is a medication that has been used for over 30 years to remove excess iron from the body. Recently, researchers have been studying its potential benefits in treating various types of stroke and brain hemorrhage.
What Conditions Does Deferoxamine Mesylate Treat?
Based on ongoing clinical trials, Deferoxamine Mesylate is being investigated as a potential treatment for several conditions related to stroke and brain hemorrhage:
- Intracerebral Hemorrhage (ICH): This is a type of stroke caused by bleeding within the brain tissue.
- Subarachnoid Hemorrhage (SAH): This is bleeding that occurs in the space between the brain and the surrounding membrane.
- Acute Ischemic Stroke: This type of stroke occurs when blood flow to part of the brain is blocked.
How Does Deferoxamine Mesylate Work?
Deferoxamine Mesylate works as an iron chelator, which means it binds to excess iron in the body and helps remove it. In the context of stroke and brain hemorrhage, researchers believe that Deferoxamine Mesylate may help in several ways:
- Reducing iron accumulation in the brain after bleeding, which may contribute to brain injury.
- Improving cerebrovascular regulation, which refers to how well blood flow in the brain is controlled.
- Potentially protecting brain cells from damage caused by lack of oxygen (ischemia).
How is Deferoxamine Mesylate Administered?
In the clinical trials, Deferoxamine Mesylate is typically administered through intravenous (IV) infusion. The dosage and duration of treatment vary depending on the specific study:
- In some trials, it's given at a dose of 32 mg/kg/day for 3 consecutive days.
- Other studies use different dosages, ranging from 7 mg/kg to 125 mg/kg per day.
- Some trials administer it for up to 5 consecutive days.
Ongoing Research and Clinical Trials
Several clinical trials are currently investigating the effectiveness of Deferoxamine Mesylate for various stroke-related conditions:
- The iDEF Trial is studying its use in intracerebral hemorrhage.
- A study is examining its potential to prevent delayed cerebral ischemia after subarachnoid hemorrhage.
- The ACT-GLOBAL trial is investigating its use in combination with another drug called colchicine for intracerebral hemorrhage.
Potential Benefits of Deferoxamine Mesylate
While research is still ongoing, scientists hope that Deferoxamine Mesylate may provide several benefits for stroke patients:
- Improved functional outcomes after stroke, as measured by scales like the modified Rankin Scale (mRS).
- Reduced brain damage and better recovery after intracerebral hemorrhage.
- Prevention of delayed cerebral ischemia after subarachnoid hemorrhage.
Possible Side Effects and Safety Concerns
As with any medication, Deferoxamine Mesylate may have side effects. The clinical trials are carefully monitoring for any adverse events, including:
- Allergic reactions during infusion.
- Hypotension (low blood pressure).
- Visual or auditory changes.
- Respiratory complications.
It's important to note that these potential side effects are being closely monitored in the clinical trials, and the safety of the drug is a key focus of the research.